NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public.
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing.
DETROIT, MICHIGAN - December 16, 2025 ( NEWMEDIAWIRE ) - Jupiter Neurosciences Inc. (NASDAQ: JUNS), the clinical-stage pharmaceutical company developing JOTROL, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects, is ending the year on a high note hitting several milestones in its first year as a public company.
DETROIT, MICHIGAN - November 6, 2025 ( NEWMEDIAWIRE ) - When it comes to brain health, Jupiter Neurosciences Inc. (NASDAQ: JUNS) knows a thing or two about it. After all, the clinical-stage pharmaceutical company developing JOTROL™, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects, has developed Nugevia™, a direct-to-consumer longevity product line, aimed at improving mitochondrial support, mental clarity and "beauty from within."
DETROIT, MICHIGAN - August 21, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, Chairman and CEO, and Alison Silva, President and CBO at Jupiter Neurosciences Inc . (NASDAQ: JUNS), sat down with Benzinga to discuss how the company is addressing longevity and brain health with JOTROL™ and its new direct-to-consumer product line, Nugevia.
DETROIT, MICHIGAN - August 19, 2025 ( NEWMEDIAWIRE ) - Jupiter Neurosciences Inc . (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™ – an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects – is solidifying its two-pronged business approach with the launch of Nugevia™, its direct-to-consumer longevity product line.
